Platelet?rich plasma (PRP) injection is associated with improvements in melasma within 6 weeks of treatment and the use of this therapy is associated with increased patient satisfaction, according to pilot study findings published in the Journal of Cosmetic Dermatology.

The randomized split-face single-blinded prospective trial enrolled a total of 10 women with bilateral mixed?type melasma (mean age, 46.2 years [range, 33 to 58 years]). Clinicians injected PRP intradermally on one side of the face during four treatment sessions every 2 weeks. The control side of the face was injected with normal saline. The modified Melasma Area and Severity Index (mMASI), Mexameter®, and Antera® 3D were used to assess outcomes. Patient satisfaction was also evaluated at baseline and at 2, 4, 6, and 10 weeks.